GH-dependent STAT5 signaling plays an important role in hepatic lipid metabolism

Endocrinology

Volumn 152, Issue 1, 2011, Pages 181-192

  Barclay, Johanna L ^a   Nelson, Caroline N ^a   Ishikawa, Mayumi ^a   Murray, Lauren A ^a   Kerr, Linda M ^a   McPhee, Timothy R ^a   Powell, Elizabeth E ^b   Waters, Michael J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID SYNTHASE; GROWTH HORMONE; GROWTH HORMONE RECEPTOR; LIPID; LIPOPROTEIN LIPASE; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; STAT5A PROTEIN; STAT5B PROTEIN; VERY LOW DENSITY LIPOPROTEIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL LINE; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE EXPRESSION; GROWTH HORMONE DEFICIENCY; LIPID METABOLISM; LIPID STORAGE; LIPID TRANSPORT; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STEATOSIS;

ANIMALS; CELL LINE; FATTY LIVER; GENE EXPRESSION REGULATION; GROWTH HORMONE; HEPATOCYTES; LIPID METABOLISM; LIVER; MALE; MICE; MICE, KNOCKOUT; PROTEIN ARRAY ANALYSIS; RECEPTORS, SOMATOTROPIN; STAT1 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR;

EID: 78650850032     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2010-0537     Document Type: Article

References (51)

1. Anderson N, Borlak J 2008 Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharm Rev 60:311-357
2. Desvergne B, Michalik L, Wahli W 2006 Transcriptional regulation of metabolism. Physiol Rev 86:465-514
3. Vijayakumar A, Novosyadlyy R, Wu Y, Yakar S, Le Roith D 2010 Biological effects of GH on carbohydrate and lipid metabolism. Growth Horm IGF Res 20:1-7
4. Wang Z, Masternak MM, Al-Regaiey KA, Bartke A 2007 Adipo-cytokines and the regulation of lipid metabolism in GH transgenic and calorie-restricted mice. Endocrinology 148:2845-2853
5. Adams LA, Feldstein A, Lindor KD, Angulo P 2004 NAFLDamong patients with hypothalamic and pituitary dysfunction. Hepatology 39:909-914
6. Ichikawa T, Hamasaki K, Ishikawa H, Ejima E, Eguchi K, Nakao K 2003 NASH and hepatic steatosis in patients with adult growth hormone deficiency. Gut 52:914
7. Langendonk JG, Meinders AE, Burggraaf J, Frölich M, Roelen CA, Schoemaker RC, Cohen AF, Pijl H 1999 Influence of obesity and body fat distribution on GH kinetics in humans. Am J Physiol 277: E824-E829
8. Fukuda I, Hizuka N, Yasumoto K, Morita J, Kurimoto M, Takano K 2008 Metabolic co-morbidities revealed in patients with childhood-onset adult GH-deficiency after cessation of GH replacement. Endocr J 55:977-984
9. Takahashi Y, Iida K, Takahashi K, Yoshioka S, Fukuoka H, Takeno R, Imanaka M, Nishizawa H, Takahashi M, Seo Y, Hayashi Y, Kondo T, Okimura Y, Kaji H, Kitazawa R, Kitazawa S, Chihara K 2007 GH reverses NASH in a patient with adult GH deficiency. Gastroenterology 132:938-943
10. Laron Z, Ginsberg S, Webb M 2008 Nonalcoholic fatty liver in patients with Laronsyndrome and GHgene deletion. Growth Horm IGF Res 18:434-438
11. Berryman D E, List E O, Coschigano K T, Behar K, Kim J K, Kopchick JJ 2004 Comparing adiposity profiles in three mouse models with altered GH signaling. Growth Horm IGF Res 14:309-318
12. Zhou Y, Xu BC, Maheshwari HG, He L, Reed M, Lozykowski M, Okada S, Cataldo L, Coschigamo K, Wagner TE, Baumann G, Kopchick JJ 1997 A mammalian model for Laron syndrome. Proc Natl Acad Sci USA 94:13215-13220
13. Fan Y, Menon RK, Cohen P, Hwang D, Clemens T, Di Girolamo D J, Kopchick JJ, Le Roith D, Trucco M, Sperling MA 2009 Liver-specific deletion of the GH receptor reveals essential role of GH in hepatic metabolism. J Biol Chem 284:19937-19944
14. Herrington J, Carter-Su C 2001 Signaling pathways activated by GH receptor. Trends Endocrinol Metab 12:252-257
15. Rowlinson SW, Yoshizato H, Barclay JL, Brooks AJ, Behncken SN, Kerr LM, Millard K, Palethorpe K, Nielsen K, Clyde-Smith J, Hancock JF, Waters MJ 2008 An agonist-induced conformational change in the GH receptor determines choice of signaling pathway. Nature Cell Biol 10:740-747
16. Lichanska AM, Waters M J 2008 How GH controls growth, obesity and sexual dimorphism. Trends in Genetics 24:41-47
17. Waxman DJ, O'Connor C 2006 GH regulation of sex-dependent liver gene expression. Mol Endocrinol 20:2613-2629
18. Clodfelter KH, Holloway MG, Hodor P, Park SH, Ray WJ, Waxman DJ 2006 Sex dependent liver gene expression is largely dependent on STAT5b. Mol Endocrinol 20:1333-1351
19. Rowland JE, Lichanska AM, Kerr LM, White M, d'Aniello EM, Maher SL, Brown R, Teasdale RD, Noakes PG, Waters M J 2005 In vivo analysis of GH receptor signaling domains and their associated transcripts. Mol Cell Biol 25:66-77
20. Barclay JL, Kerr LM, Arthur L, Rowland JE, Nelson CN, Ishikawa M, d'Aniello EM, White M, Noakes PG, Waters MJ 2010 In vivo targeting of theGH receptor box1 sequence demonstrates that GHR does not signal exclusively through JAK2. Mol Endocrinol 24:204-217
21. Cui Y, Riedlinger G, Miyoshi K, Tang W, Li C, Deng CX, Robinson GW, Hennighausen L 2004 Inactivation of STAT5 in mouse mammary epithelium during pregnancy. Mol Cell Biol 24:8037-8047
22. Salmon DM, Flatt JP 1985 Effect of dietary fat content on the incidence of obesity among ad libitum fed mice. Int J Obes 9:443-449
23. Churukian CJ 1999 Lillie's oil red O method for neutral lipids. J Histotechnol 22:309-311
24. Millar JS, Cromley DA, McCoy MG, Rader DJ, Billheimer JT 2005 Determining hepatic triglyceride production in mice: comparison of poloxamer 407 with Triton WR-1339. J Lipid Res 46:2023-2028
25. Barclay JL, Anderson ST, Waters MJ, Curlewis JD 2009 SOCS3 as a tumor suppressor. Int J Cancer 124:1756-1766
26. Sato O, Takanashi N, Motojima K 2007 Third promoter and differential regulation of mouse and human CD36 genes. Mol Cell Biochem 299:37-43
27. Delesque-Touchard N, Park SH, Waxman DJ 2000 Synergistic action of HNFs 3 and 6 on CYP2C12 gene expressionand suppression by GH-activated STAT5b. J Biol Chem 275:34173-34182
28. Hosui A, Hennighausen L 2008 Genomic dissection of the cytokine-controlled STAT5 signaling network in liver. Physiol Genomics 34: 135-143
29. Cui Y, Hosui A, Sun R, Shen K, Gavrilova O, Chen W, Cam MC, Gao B, Robinson GW, Hennighausen L 2007 Loss of STAT5 leads to hepatosteatosis and impaired liver regeneration. Hepatology 46: 504-513
30. Frick F, Lindén D, Améen C, Edén S, Mode A, Oscarsson J 2002 Interaction between GH and insulin in the regulation of lipoprotein metabolism in the rat. Am J Physiol Endocrinol Metab 283:E1023-E1031
31. Shipley JM, Waxman DJ 2004 Simultaneous, bidirectional inhibitory crosstalk between PPARs and STAT5b. Toxicol Appl Pharmacol 199:275-284
32. Hogan JC, Stephens JM 2005 The regulation of fatty acid synthase by STAT5a. Diabetes 54:1968-1975
33. Huo JS, McEachin RC, Cui TX, Duggal NK, Hai T, States DJ, Schwartz J 2006 Profiles of GH-regulated genes reveal time-dependent responses and reveal a mechanism for regulation of ATF3 by GH. J Biol Chem 281:4132-4141
34. Ning ZQ, Li J, McGuinness M, Arceci RJ 2001 STAT3 activation is required for mutant c-kit induced tumorigenicity. Oncogene 20: 4528-4536
35. Cheon H, Stark GR 2009 Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes. Proc Natl Acad Sci USA 106:9373-9378
36. Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G, Vonderfecht S, Hecht R, Li Y S, Lindberg R A, Chen J L, Jung D Y, Zhang Z, Ko H J, Kim JK, Véniant MM 2009 FGF21 reverses hepatic steatosis, increases energy expenditure and improves insulin sensitivity in DIO mice. Diabetes 58:250-259
37. Yu S, Matsusue K, Kashireddy P, Cao WQ, Yeldandi V, Yeldandi AV, Rao MS, Gonzalez FJ, Reddy JK 2003 Adipocyte-specific gene expression and adipogenic steatosis in mouse liver due to PPAR71 overexpression. J Biol Chem 278:498-505
38. Gavrilova O, Haluzik M, Matsusue K, Cutson JJ, Johnson L, Dietz KR, Nicol CJ, Vinson C, Gonzalez FJ, Reitman ML 2003 Liver PPAR7 contributes to hepatic steatosis, triglyceride clearance and regulation of body fat mass. J Biol Chem 278:34268-34276
39. Christianson JL, Nicoloro S, Straubhaar J, Czech MP 2008 SCD2 is required for PPAR7 expression and adipogenesis in 3T3-L1 cells. J Biol Chem 283:2906-2916
40. Tan NS, Michalik L, Desvergne B, Wahli W 2005 Multiple expression control mechanisms of PPARs. J Steroid Biochem Mol Biol 93:99-105
41. Zhou J, Febbraio M, Wada T, Zhai Y, Kuruba R, He J, Lee JH, Khadem S, Ren S, Li S, Silverstein RL, Xie W 2008 Hepatic fatty acid transporter CD36 is a common target of LXR, PXR and PPAR7 in promoting steatosis. Gastroenterology 134:556-567
42. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, Evans RM 1994 Differential expression and activation of a family of murine PPARs. Proc Natl Acad Sci USA 91:7355-7359
43. Bradbury MW 2006 Lipid metabolism and liver inflammation. 1. Hepatic FA uptake; possible role in steatosis. Am J Gastrointest Liver Physiol 290: G194-G198
44. Koonen DP, Jacobs RL, Febbraio M, Young ME, Soltys CL, Ong H, Vance DE, Dyck JR 2007 Increased hepatic CD36 expression contributes to dyslipidemia associated with DIO. Diabetes 56:2863-2871
45. Zhou J, Zhai Y, Mu Y, Gong H, Uppal H, Toma D, Ren S, Evans RM, Xie W 2006 A novel pregnane X receptor-mediated and SREBP-independent lipogenic pathway. J Biol Chem 281:15013-15020
46. Pardina E, Baena-Fustegueras JA, Llamas R, Catalan R, Galard R, Galard R, Lecube A, Fort JM, Llobera M, Allende H, Vargas V, Peinado-Onsurbe J 2009 Lipoprotein lipase expression in livers of morbidly obese patients could be responsible for liver steatosis. Obes Surg 19:608-616
47. Westerbacka J, Kolak M, Kiviluoto T, Arkkila P, Siren J, Hamsten A, Fisher RM, Yki-Jarvinen H 2007 Genes involved in fatty acid partitioning and binding, lipolysis are overexpressed in human fatty liver of insulin-resistant diabetics. Diabetes 56:2759-2765
48. Kim JK, Fillmore JJ, Chen Y, Yu C, Moore IK, Pypaert M, Lutz EP, Kako Y, Velez-Carrasco W, Goldberg IJ, Breslow JL, Shulman GI 2001 Tissue-specific overexpression of LPL causes tissue-specific insulin resistance. Proc Natl Acad Sci USA 98:7522-7527
49. Kobayashi K, Oka K, Forte T, Ishida B, Teng B, Ishimura-Oka K, Nakamuta M, Chan L 1996 Reversal of hypercholesterolemia in LDL receptor knockout mice by gene transfer of the VLDL receptor. J Biol Chem 271:6852-6860
50. Goudriaan JR, Espirito Santo SM, Voshol PJ, Teusink B, van Dijk KW, van Vlijmen BJ, Romijn JA, Havekes LM, Rensen PC 2004 The VLDL receptor plays a major role in chylomicron metabolism by enhancing LPL-mediated triglyceride hydrolysis. J Lipid Res 45:1475-1481
51. Hosui A, Kimura A, Yamaji D, Zhu BM, Na R, Hennighausen L 2009 Loss of STAT5 causes liver fibrosis and cancer development through increased TGFb and STAT3 activation. J Exp Med 206: 819-831